Stay updated with breaking news from Chas Schultz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in... | February 28, 2023
10.02.2023 - SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and ...
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the...
SAN DIEGO, Oct. 13, 2022 -- Crinetics Pharmaceuticals, Inc. today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase... | October 13, 2022
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as...